ALNY Share Price

Open 41.60 Change Price %
High 42.82 1 Day -0.01 -0.02
Low 40.62 1 Week -6.31 -13.18
Close 41.57 1 Month 10.16 32.35
Volume 1586992 1 Year -64.35 -60.75
52 Week High 102.51
52 Week Low 31.38
ALNY Important Levels
Resistance 2 43.61
Resistance 1 42.77
Pivot 41.67
Support 1 40.37
Support 2 39.53
NASDAQ USA Most Active Stocks
SIRI 4.30 -5.49%
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
SUSQ 14.20 -0.77%
QQQ 115.67 0.17%
WRES 0.09 0.00%
More..
NASDAQ USA Top Gainers Stocks
QKLS 0.21 110.00%
LOCM 0.09 50.00%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
PERF 1.90 22.58%
ASNA 7.01 20.24%
SBSA 4.60 17.95%
CEMP 7.55 15.27%
XXIA 15.55 14.76%
More..
NASDAQ USA Top Losers Stocks
PTIX 0.00 -100.00%
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
AMCF 0.03 -50.00%
OPXAW 0.01 -50.00%
VALV 0.03 -50.00%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
More..

Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY)

ALNY Technical Analysis 4
As on 2nd Dec 2016 ALNY Share Price closed @ 41.57 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 62.16 & Sell for SHORT-TERM with Stoploss of 48.74 we also expect STOCK to react on Following IMPORTANT LEVELS.
ALNY Target for December
1st Target up-side 55.57
2nd Target up-side 63.77
3rd Target up-side 71.97
1st Target down-side 32.17
2nd Target down-side 23.97
3rd Target down-side 15.77
ALNY Other Details
Segment EQ
Market Capital 846890560.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.alnylam.com
ALNY Address
ALNY
300 Third Street
3rd Floor
Cambridge, MA 02142
United States
Phone: 617-551-8200
Fax: 617-551-8101
Interactive Technical Analysis Chart Alnylam Pharmaceuticals, Inc. ( ALNY NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Alnylam Pharmaceuticals, Inc.
ALNY Business Profile
Alnylam Pharmaceuticals, Inc. (Alnylam) is a biopharmaceutical company developing therapeutics based on ribonucleic acid interface (RNAi). Its Alnylam 5x15, is focused on the development and commercialization of novel RNAi therapeutics for the treatment of genetically defined diseases. Its core programs in clinical or pre-clinical development are: ALN-TTR for the treatment of transthyretin-mediated amyloidosis (ATTR); ALN-APC for the treatment of hemophilia; ALN-PCS for the treatment of severe hypercholesterolemia; ALN-HPN for the treatment of refractory anemia, and ALN-TMP for the treatment of hemoglobinopathies, including beta-thalassemia and sickle cell anemia. The Company has three partner-based programs in clinical or pre-clinical development, including ALN-RSV01 for the treatment of respiratory syncytial virus (RSV), infection, ALN-VSP for the treatment of liver cancers and ALN-HTT for the treatment of Huntington’s disease (HD). The Company’s advanced core product development program, ALN-TTR, targets the transthyretin (TTR), gene for the treatment of ATTR. ATTR is a hereditary, systemic disease caused by a mutation in the TTR gene, of which over 100 mutations have been identified. TTR protein is produced primarily in the liver and is normally a carrier for thyroid hormone and retinol binding protein. The Phase1 clinical trial for ALN-TTR01 was conducted in Portugal, Sweden, the United Kingdom and France as a randomized, blinded, placebo-controlled, single-dose escalation study in up to 36 patients with ATTR.